ATNM.US Actinium Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
1.64 USD
Close of Nov 13, 2026
0.7350 1.72
Market cap
USD 51.6M
P/E
4.4x
P/B
1.65x
ROE
147.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ATNM.US undervalued?

Graham number
Price1.64
Graham value2.88
Discount43.0%

ATNM.US trades 43.0% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Actinium Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Actinium Pharmaceuticals Inc yet.

Actinium Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disor…

Full company profile